Rationale: There are conflicting data on the effects of vascular endothelial growth factor (VEGF) in vascular remodeling. Furthermore, there are species-specific differences in leukocyte and vascular cell biology and little is known about the role of VEGF in remodeling of human arteries. Objective: We sought to address the role of VEGF blockade on remodeling of human arteries in vivo. Methods and Results: We used an anti-VEGF antibody, bevacizumab, to study the effect of VEGF blockade on remodeling of human coronary artery transplants in severe combined immunodeficient mice. Bevacizumab ameliorated peripheral blood mononuclear cell-induced but not interferon-␥-induced neointimal formation.
V ascular endothelial growth factor (VEGF, also referred to as VEGFA) is produced in response to hypoxia, growth factors (eg, epidermal growth factor, platelet-derived growth factor), and proinflammatory cytokines (eg, interleukin-1␣ and interleukin-6) by endothelial cells (ECs), leukocytes (monocyte/macrophages and T cells), and a number of other cell types. 1 In addition to its well-known role in promoting angiogenesis, VEGF plays an important role in leukemic cell growth and inflammatory disorders. VEGF contributions to the pathogenesis of vascular pathology include promoting angiogenesis, reendothelialization, vascular smooth muscle cell (VSMC) migration, and inflammation in the vessel wall. 2 Vascular remodeling, as in graft arteriosclerosis and postangioplasty restenosis, is a common feature of many vascular diseases. There are conflicting data on the role of VEGF in vascular remodeling. [3] [4] [5] [6] [7] [8] As such, VEGF may promote neointima, inhibit neointima, or have opposing effects based on its endogenous or exogenous origin. 2 Given this controversy on the role of VEGF in vascular remodeling and species-specific differences in leukocyte and vascular cell biology between mice and humans, it is difficult to speculate what role, if any, VEGF plays in remodeling of human arteries. In the present study, we sought to address the role of human VEGF in remodeling of human arteries in vivo using chimeric human/ mouse models of vascular remodeling and a specific antihuman (but not anti-mouse) VEGF antibody. 9, 10 We demonstrate that specific blocking of human VEGF ameliorates neointima formation in transplanted human coronary arteries and that this effect is, at least in part, through direct effects on T-cell trafficking. Finally, we demonstrate that VEGF enhances human T-cell binding to the endothelium under flow and identify a subpopulation of T cells that express potentially functional VEGF receptor (VEGFR)-1.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Animal Models
Human coronary artery transplantation in immunodeficient mice was performed as described. 11 In brief, adjacent segments of human coronary artery were implanted into the infrarenal aortae of 8-to 12- week-old C.B-17 severe combined immunodeficient (SCID)/ beige mice. A group of animals received 1ϫ10 8 human peripheral blood mononuclear cells (PBMCs) per mouse (or control buffer), injected intraperitoneally 1 week after transplantation. Other animals were injected with replication incompetent Ad5.CMVhuman interferon-␥ (IFN-␥) or Ad5.CMV-LacZ through the jugular vein. Bevacizumab or control human immune globulins were administered at a dose of 5 mg/kg IP 3 times per week, starting with PBMC transfer or injection of adenovirus. Animals were euthanized at 4 weeks after PBMC transfer or adenovirus injection (5 weeks after coronary artery transplantation), and transplanted arteries were removed and frozen in OCT for further analysis. All experiments were performed under protocols approved by Yale University Institutional Animal Care and Use and Human Investigation Committees.
Results

VEGF and VEGFR Expression in Immune-Mediated Vascular Remodeling
Transplantation of segments of human coronary artery to the abdominal aorta of SCID mice followed by adoptive transfer of allogeneic human PBMCs (of which only memory T cells reconstitute the host) led to significant neointima formation and expansive remodeling over a period of 4 weeks, as previously described. 11 The intima and total vessel areas increased from 0.21Ϯ0.05 mm 2 and 0.62Ϯ0.12 mm 2 in control animals that were not given PBMC to 0.67Ϯ0.16 mm 2 and 1.12Ϯ0.17 mm 2 at 4 weeks after PBMC inoculation (nϭ5, Pϭ0.004 and 0.005, respectively) 12 (Figure 1a and Online Figure I ). Both VEGF and its receptor, VEGFR-1, were readily detectable by immunostaining in transplanted coronary arteries, whether in the presence or absence of PBMC transfer, and predominantly localized to the neointima and media. VEGFR-2 expression was less apparent and mainly localized to the luminal endothelium ( Figure 1b ). There was no significant difference in 18S rRNA-normalized VEGFR-1 mRNA levels detected by quantitative RT-PCR between the 2 groups of animals (nϭ5 per group). Normalized VEGFR-2 levels were slightly but significantly decreased in transplanted arteries after PBMC transfer (nϭ5, PϽ0.05, Figure 1c ).
VEGF Inhibition and Modulation of Immune-Mediated Vascular Remodeling
To address the role of VEGF in the pathogenesis of immune-mediated vascular remodeling, we investigated the effect of bevacizumab, a function-blocking anti-human (but not murine) VEGF antibody, 9,10 on PBMC-induced vascular remodeling in SCID mice transplanted with human coronary arteries. Bevacizumab (5 mg/kg IP, 3 times a week) significantly reduced neointima (0.74Ϯ0.07 mm 2 and 0.52Ϯ0.09 mm 2 , respectively, for the control and bevacizumab-treated groups, nϭ10, Pϭ0.004) and increased lumen areas (0.17Ϯ0.06 mm 2 and 0.26Ϯ0.07 mm 2 , respectively, for the control and bevacizumab-treated groups, nϭ10, Pϭ0.049) at 4 weeks after PBMC reconstitution, demonstrating a nonredundant causal role of human VEGF in this model of immune-mediated human vascular remodeling ( Figure 2 and Online Figure I) .
T-cell recruitment, activation, and IFN-␥ secretion are key steps in PBMC-induced vascular remodeling. 13 Therefore, to address the mechanism(s) of the modulatory effect of VEGF inhibition, we assessed the effect of bevacizumab on T-cell infiltration, activation, and cytokine production in human coronary artery transplants. There was a significant reduction in the number of intimal human CD45ϩ cells (leukocytes) in animals treated with bevacizumab (824Ϯ152 and 367Ϯ121, respectively, for the control and bevacizumab-treated groups, nϭ7, Pϭ0.02, Figure 3a and 3b), indicating that VEGF blockade inhibits leukocyte accumulation in transplants. This was confirmed by quantitative RT-PCR that demonstrated a significant reduction in GAPDH-normalized human CD3 transcripts in animals treated with bevacizumab (to 45Ϯ15%, nϭ7, Pϭ0.039, Figure 3c ). Similarly, a trend toward reduction of the number of CD69ϩ cells was detected in animals treated with bevacizumab ( Figure 4a and 4b). However, bevacizumab did not affect leukocyte activation beyond its effect on reducing leukocyte infiltration (ratio of infiltrating CD69ϩ to CD45ϩ cells: 0.18Ϯ0.04 and 0.35Ϯ0.12, respectively, for the control and bevacizumab-treated groups, nϭ7, PϭNS, Figure 4c ). There was no clear difference in CD31 (EC), ␣-actin (VSMC), VEGF, or VEGFR expression pattern in arteries from control and bevacizumab-treated animals (data not shown).
Next, we assessed the effect of VEGF inhibition on IFN-␥ production in the arterial transplants by quantitative RT-PCR. There was no significant difference in the ratio of IFN-␥ to CD3 transcripts between animals treated with bevacizumab and those treated with the control IgG, indicating that VEGF inhibition does not alter IFN-␥ expression by T cells in this model (IFN-␥ to CD3 transcript ratio: 0.21Ϯ0.04 and 0.19Ϯ0.07, respectively, for the control and bevacizumabtreated groups; nϭ6, PϭNS; Figure 4d ). 
Non-standard Abbreviations and Acronyms
VEGF Inhibition and IFN-␥-Induced Vascular Remodeling
IFN-␥ is a key mediator of PBMC-induced vascular remodeling that can induce remodeling in transplanted arteries in the absence of allogeneic PBMC transfer. 14 Unlike the neointima of PBMC-induced remodeled arteries (which is mainly composed of infiltrating human memory T cells), the neointima in IFN-␥-induced arterial remodeling is rich in VSMCs. 13, 15, 16 To establish whether the observed effect of bevacizumab on reducing vascular remodeling is dependent on its modulatory effect on leukocyte recruitment, we assessed the effect of VEGF blockade on IFN-␥-induced arterial remodeling. As expected, infection with Ad-IFN-␥ in SCID mice transplanted with human coronary artery led to a significant increase in the transplant intima and total vessel areas over a period of 4 weeks (intima area: 0.25Ϯ0.02 versus 0.12Ϯ0.02 mm 2 , and total vessel area: 0.71Ϯ0.03 mm 2 versus 0.43Ϯ0.05 mm 2 , respectively, for IFN-␥ and control, Lac Z adenovirus-treated animals, nϭ4 in each group, Pϭ0.037 and 0.02, respectively) ( Figure 5a and Online Figure I) . A similar pattern of VEGF and VEGFR expression was detected in IFN-␥-induced remodeled arteries (data not shown). However, contrary to its effect on PBMC-induced vascular remodeling, bevacizumab treatment failed to demonstrate any inhibitory effect on IFN-␥-induced vascular remodeling (intima area, 0.38Ϯ0.06 mm 2 versus 0.34Ϯ0.07 mm 2 , and total vessel area: 0.93Ϯ0.08 mm 2 versus 0.83Ϯ0.10 mm 2 , respectively, for the control and bevacizumab-treated groups, nϭ5 in each group, PϭNS, Figure 5b ), suggesting that the observed inhibitory effect of bevacizumab on vascular remodeling is dependent on the presence of T cells.
VEGF and T-Cell Adhesion to Endothelium
T-cell recruitment to transplanted arteries involves a cascade of events, including chemotaxis, adhesion to ECs, and transmigration, which may be targets of VEGF stimulation. The IFN-␥ and VEGF-inducible IP-10 is a readily detectable chemokine in transplanted arteries and is believed to play a role in the recruitment T cells. 15, 17 We assessed the effect of bevacizumab treatment on IP-10 expression by quantitative RT-PCR (data not shown). Unexpectedly, bevacizumab treatment had no inhibitory effect on IP-10 expression in transplanted arteries. To address whether VEGF has a direct effect on T-cell adhesion to ECs and/or transendothelial migration, we assessed the effect of VEGF on T cell-EC interactions under flow conditions. To dissociate a potential effect of VEGF on T cells from its known effects on ECs, TNF-treated (1 ng/mL, 20 hours) ECs were pretreated with an inhibitor of VEGFR signaling, SU5416, 18, 19 under conditions that completely inhibited VEGF-induced activation of ERK (Online Figure II) and Akt (data not shown). VEGF (100 ng/mL, 5 minutes) had no effect on T-cell transmigration through the endothelium under shear stress (data not shown) but significantly increased the number of T cells adhering to the ECs (Figure 6a ). The VEGF effect could be recapitulated when recombinant intercellular adhesion molecule 1 (ICAM-1) alone or a combination of recombinant ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1), rather than ECs, was used to capture T cells under shear stress (Figure 6b ). Pretreatment of T cells with SU5416 or preincubation of ECs with an anti-ICAM-1 antibody inhibited VEGF-induced T-cell adhesion to TNF-treated ECs (Online Figure III) .
VEGF Receptors in T cells
VEGF-induced enhanced T-cell capture by ECs is highly suggestive of direct effects of VEGF on T cells or at least a subpopulation of T cells. This would imply that T cells express a functional VEGF receptor. In fact, immunostaining of PBMC smear demonstrated the presence of a population of CD3ϩ T cells that express VEGFR-1 on their surface ( Figure  7a ). By flow cytometry, 1.2Ϯ0.2% of CD3ϩ cells (nϭ3) were found to express VEGFR-1 (Figure 7b ). Quantitative RT-PCR confirmed expression of VEGFR-1 (but failed to convincingly detect expression of VEGFR-2) mRNA by purified CD4ϩ and CD4ϩCD45RA Ϫ memory T cells (Figure 7c ). Jurkat and HSB-2 human transformed T-cell lines also expressed detectable levels of VEGFR-1 mRNA and protein but lacked VEGFR-2 (Figure 7c and 7d ). Using directly conjugated antibody for VEGFR-1 and flow cytometry, we confirmed surface expression of VEGFR-1 by Jurkat and HSB-2 cells (Figure 7e ). Stimulation of HSB-2 cells with VEGF triggered detectable but transient phosphorylation of ERK, demonstrating the functionality of VEGFR-1 in this cell line (Figure 7f ). Finally, consistent with the presence of a population of VEGFR-1-expressing T cells, VEGF induced ERK phosphorylation in a subset of CD3ϩ T cells, as detected by intracellular staining and flow cytometry ( Figure  7g and Online Figure IV) . Similarly, ERK phosphorylation could be induced in a subset of CD3ϩ T cells on stimulation with placenta growth factor, a VEGFR-1-specific ligand, 1 demonstrating the functionality of VEGFR-1 in human T cells (Figure 7g ).
Discussion
In the present study, we provide new information on the role of VEGF in vascular remodeling, demonstrating that human VEGF inhibition with bevacizumab ameliorates immunemediated arteriosclerosis. Although early studies suggested that VEGF may prevent vascular remodeling by enhancing reendothelialization, 3 other studies pointed to a more nuanced picture where, depending on the species and source of VEGF, it may enhance or inhibit neointima formation. [5] [6] [7] [8] The VEGF effect on vascular remodeling is probably multifaceted and may include modulation of VSMC migration, 20,21 angiogenesis, and immune and inflammatory responses. 4, 17, [22] [23] [24] [25] The immune-modulatory effects of VEGF have been linked to modulation of monocyte 4, 22, 25, 26 and/or lymphocyte recruitment 17,25 via regulation of angiogenesis, 25 chemokine production (IP-10, monocyte chemotactic protein-1), 17,22,25 EC acti-vation, 27 and dendritic cell maturation. 28 In parallel, through induction of nitric oxide production by ECs, VEGF can function as an antiinflammatory agent and limit VSMC proliferation. 29, 30 An extra layer of complexity in interpreting these observations is raised by established differences in VEGF biology between mice and humans. For example, it is reported that the VEGF effect on chemokine production by ECs is species-specific. VEGF alone can induce IP-10 in murine but not human ECs, where it can potentiate the IFN-␥ effect. 17 The chimeric human/mouse models of immune-mediated vascular injury provided us with a unique opportunity to investigate the effect of human VEGF blockade on vascular remodeling in human coronary arteries. Because of the species-specificity of the bevacizumab effect, 10 one can be reasonably confident that human VEGF, presumably produced by human vascular cells and/or adoptively transferred human PBMCs, is involved in the pathogenesis of remodeling in this model. Although we did not directly investigate the source of human VEGF in this model, ECs, VSMCs, 31 and leukocytes (monocyte/macrophages and activated T lymphocytes) [32] [33] [34] have been shown to produce VEGF under specific experimental conditions. VEGF was detectable by immunostaining in transplanted arteries. Although it is possible that VEGF is produced elsewhere and deposited in the vessel wall, 4 its nonuniform distribution suggests that it is locally produced by vascular cells exposed to ischemia/reperfusion, cytokines, or growth factors. 35 Interestingly, VEGF protein is detected in transplanted arteries 5 weeks after transplantation, presumably long after the initial exposure to ischemia, even in the absence of PBMC transfer. The molecular mechanisms of this sustained VEGF expression in the transplanted arteries remains to be determined.
Bevacizumab ameliorated PBMC-induced but not the closely related IFN-␥-induced vascular remodeling. In addition, VEGF blockade had no apparent effect on T-cell activation and polarization. Memory CD3ϩ T lymphocytes expressing the CD45RO marker constitute the bulk of transplant-infiltrating human leukocytes in this model, where very few CD68ϩ macrophages and dendritic cells are detectable, 15 whereas VSMCs constitute the major cells of neointima in IFN-␥-induced vascular remodeling. 13, 16 This led us to identify leukocyte recruitment as the critical step in the observed modulatory effect of bevacizumab on GA. Although we did not directly address this possibility here, VEGF might facilitate lymphocyte recruitment through induction of endothelial adhesion molecules, ICAM-1, and VCAM-1. 27 The direct effects of VEGF on monocytic cells 36, 37 are well recognized. However, much less is known about the direct VEGF effect on T-cell responses. It is reported that VEGF is involved in T-cell recruitment in alloimmunity. 17, 38 Whereas IP-10 production plays a part in this VEGF effect, other yet to be discovered mechanisms appear to play a major role in the VEGF effect in alloimmunity. 17 Similar to our own findings, previous studies have failed to demonstrate an effect of VEGF on lymphocyte activation. 17 It is reported that VEGF modifies rat T-cell cytokine secretion profile toward a Th1 phenotype. 39 However, we did not detect any effect of VEGF in vitro (data not shown) or its blockade in vivo on IFN-␥ production. Searching for potential additional mechanisms, and in the absence of a demonstrable inhibitory effect of bevacizumab on IP-10 production, we hypothesized that VEGF may directly act on T lymphocytes and modulate their recruitment to the vessel wall. Therefore, to investigate whether VEGF can affect other critical steps in T-cell recruitment to the artery, namely, T-cell adhesion to the endothelium and transendothelial migration, we studied the effect of VEGF under both static and flow conditions. CD4ϩ effector memory cells expressing integrin receptors for endothelial adhesion molecules readily migrate to the sites of inflammation and mediate allogeneic responses in reconstituted SCID/beige mice. 40 To dissociate the VEGF effects on ECs from its potential effects on T cells, VEGF signaling in TNF-activated ECs was inhibited with SU5416. 18 VEGF had little effect on T-cell binding to ECs under static conditions (data not shown). However, it significantly enhanced T-cell capture by activated ECs under flow conditions. This effect was recapitulated when a combination of recombinant ICAM-1 and VCAM-1 replaced activated ECs.
VEGFA, the prototypic member of the VEGF family of glycoproteins, interacts with several receptor tyrosine kinase VEGFRs. VEGFR-2 is the main mediator of mitogenic effects of VEGF in ECs, where VEGFR-1 may serve as a decoy receptor to fine-tune VEGF responses. 1 VEGF binding to VEGFR-2 triggers a cascade of signaling events, including p44/42 MAPK and AKT phosphorylation, which regulate EC proliferation and migration. 41 VEGFR-1 is the predominant VEGF receptor in a number of nonendothelial cells, including VSMCs and monocytes. 20, 36 Compared with VEGFR-2, less is known about signaling events triggered by VEGFR-1 activation. 1, 21, 42 Our data demonstrate that at least a subset of human T cells (as well as 2 human T-cell lines), express VEGFR-1. Although we are yet to fully characterize this population, another group of investigators recently reported that activated murine T cells express VEGFR-1 and can migrate in response to VEGF. 43 VEGF-and placenta growth factor-induced ERK phosphorylation demonstrated the functionality of VEGFR-1 in human T cells in our study.
VEGF-induced T-cell capture by recombinant ICAM-1 alone or to a greater degree to a combination of ICAM-1 and VCAM-1 (which, unlike ICAM-1, supports rolling) suggests that VEGF may alter integrin expression and/or activation of T cells. VEGF signaling through VEGFR-2 can activate ␤1, ␤3, and ␤5 integrins on ECs. 44 It is reasonable to speculate that a similar mechanism may exist for VEGFR-1 in T cells. The flow requirement in the VEGF-induced augmented adhesion suggests an additive or synergistic effect on leukocyte integrin activation and/or expression. ECs express mechanosensory complexes that contain VEGFR-2, PECAM-1, VE-cadherin, and ␣v␤3. 45 Flow-induced VEGFR-2 activation (in the absence of ligand) has been demonstrated, 46 as has an altered cellular pattern of ␣v␤3 in its active conformation. 45 Although these responses have not been demonstrated in leukocytes exposed to flow, it is likely that an analogous mechanosensory complex exists in T cells, linking VEGF responses and integrin activation. We are currently studying the effects of VEGF and flow on T-cell ␤1 and ␤2 integrin function. Together, our data strongly support a role for VEGF in regulating T-cell recruitment in immune-mediated vascular remodeling, possibly through regulation of VEGFR-1 signaling. A similar phenomenon may exist in other forms of vascular remodeling. Although we have not directly assessed the effect of T-cell VEGFR-1 blockade on neointima formation in our model, given the challenges of T-cell-specific growth factor receptor targeting in vivo, it is interesting to note that VEGFR-1 tyrosine kinase-deficient mice display reduced neointima formation after cuff placement. 47 This effect may also be, at least in part, mediated by T cells. These VEGF effects raise the possibility of novel therapeutic approaches to vascular remodeling based on inhibition of VEGF signaling. Given the important role of T cells in many aspects of immunity, 48 the implications of our findings go beyond vascular diseases and may extend to other immune and inflammatory disorders. 
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Novelty and Significance
What Is Known?
• Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis, leukemic cell growth, and inflammation. • Vascular remodeling is a common feature of many vascular diseases, including graft arteriosclerosis and postangioplasty restenosis. • Interferon-␥ plays a nonredundant role in the development of graft arteriosclerosis.
What New Information Does This Article Contribute?
• VEGF blockade inhibits neointima formation in immune-mediated vascular remodeling, at least in part, through a reduction in T-cell accumulation in the neointima. There are conflicting data on the role of VEGF in vascular remodeling, with some data indicating that VEGF promotes neointima formation whereas others point to an opposite effect. Transplantation of human coronary artery segments to infrarenal aorta of severe combined immunodeficient mice followed by adoptive transfer of allogeneic human peripheral blood mononuclear cells or treatment with interferon-␥ leads to significant remodeling of the vessel graft. We show that bevacizumab, a blocking anti-human VEGF antibody, inhibits peripheral blood mononuclear cell-induced but not interferon-␥-induced neointima formation. Human VEGF blockade leads to a reduction in T-cell accumulation in the neointima, without changes in T-cell activation or polarization. This led us to identify a novel subset of T cells that express functional VEGF receptor-1 and demonstrate that human T-cell capture by activated endothelium under flow conditions is enhanced by VEGF. Our findings establish a novel role for VEGF in inflammation and immunity and raise the possibility of novel therapeutic approaches to vascular remodeling based on inhibition of VEGF signaling in leukocytes.
